Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06300216

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Neuroendocrine Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sign an informed consent form and voluntarily participate in this study;
  • Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study;
  • Age ≥ 18 years old;
  • Treatment with octreotide microspheres.

Exclusion criteria

  • Confirmed pregnant or lactating women;
  • Participating in any research with intervention measures outside of routine clinical practice;
  • Other situations unsuitable for inclusion in the study determined by the researcher.

Treatment and study plan

Octreotide Microspheres

Drug

20mg/30mg Q4W

Primary outcomes

  1. Treatment Emergent Adverse Events

    Time frame: up to 46 months

    Treatment emergent adverse events were recorded according to Common Terminology Criteria for Adverse Events (version 5.0) of the National Cancer Institute that participants received at least one dose of protocol treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Jian Wang, Dr.

CONTACT

[email protected]

8618560088226

Sponsors and collaborators

Lead sponsor

Qilu Hospital of Shandong University

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Mar 8, 2024
Registry last updated
Mar 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.